Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine

the HEcoPerMed Consortium

Research output: Contribution to journalReview articleAcademicpeer-review

11 Citations (Scopus)


Objective: The objective of this study was to develop guidance contributing to improved consistency and quality in economic evaluations of personalised medicine (PM), given current ambiguity about how to measure the value of PM as well as considerable variation in the methodology and reporting in economic evaluations of PM. Methods: A targeted literature review of methodological papers was performed for an overview of modelling challenges in PM. Expert interviews were held to discuss best modelling practice. A systematic literature review of economic evaluations of PM was conducted to gain insight into current modelling practice. The findings were synthesised and used to develop a set of draft recommendations. The draft recommendations were discussed at a stakeholder workshop and subsequently finalised. Results: Twenty-two methodological papers were identified. Some argued that the challenges in modelling PM can be addressed within existing methodological frameworks, others disagreed. Eighteen experts were interviewed. They believed large uncertainty to be a key concern. Out of 195 economic evaluations of PM identified, 56% addressed none of the identified modelling challenges. A set of 23 recommendations was developed. Eight recommendations focus on the modelling of test-treatment pathways. The use of non-randomised controlled trial data is discouraged but several recommendations are provided in case randomised controlled trial data are unavailable. The parameterisation of structural uncertainty is recommended. Other recommendations consider perspective and discounting; premature survival data; additional value elements; patient and clinician compliance; and managed entry agreements. Conclusions: This study provides a comprehensive list of recommendations to modellers of PM and to evaluators and reviewers of PM models.

Original languageEnglish
Pages (from-to)771-788
Number of pages18
Issue number7
Publication statusPublished - 16 Apr 2021

Bibliographical note

Funding Information:
The HEcoPerMed project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement no. 824997.

Publisher Copyright:
© 2021, The Author(s).


Dive into the research topics of 'Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine'. Together they form a unique fingerprint.

Cite this